Traversa Secures $5M in Series B, Nears Close of Research Deals for Delivery Technology

The company also plans to begin a series of non-human primate studies to test its delivery technology, a move that is largely driven by the demands of potential big pharma partners for better data before forming alliances.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.